The optimal treatment of drug-induced agranulocytosis is uncertain. The observation that the growth stimulating factors can protect myeloid cells in vivo against drug-induced inhibition has led to the use of Granulocyte Colony Stimulating Factor (G-CSF) and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in therapy for neutropenia. Anecdotal reports of the use of these factors for drug-induced agranulocytosis have appeared in the literature, but the experience is very limited I 6. We report a case of carbimazole-induced agranulocytosis presenting with severe sepsis' which was successfully treated with GM-CSF.
CASE REPORT
A 38-year-old female presented with a four-day history of fever and rigors. Her past medical history included partial thyroidectomy for thyroid adenoma six years previously and six weeks prior to this admission she had been started on carbimazole 15 mg t.d.s. and propanolol 10 mg t.d.s. for thyrotoxicosis. Clinical examination revealed a temperature of 40.4 QC, heart rate of l60/min, blood pressure of 75135 mmHg, respiratory rate of 24/min, oliguria and confusion. She had no tremor and no eye signs of thyrotoxicosis. A widespread maculopapular rash and mild jaundice were also noted.
Initial investigations showed serum creatinine 170 p,molll, activated partial thromboplastin time 74 seconds, prothrombin time International Normalized 0.7 x 10 9 /1 with 94070 Iymphocytes (3070 reactive), 3070 monocytes and absolute neutropenia. Blood cultures taken on admission grew Klebsiella aerogenes. Urine microscopy and culture revealed no evidence of infection. Microbiological examination of sputum samples was unrevealing. Echocardiogram demonstrated hyperdynamic function with normal left ventricular size. Chest X-ray showed left lower and right middle lobe consolidation.
She was considered to have carbimazole-induced agranUlocytosis with severe sepsis and possible concomitant thyrotoxicosis, resulting in multi-organ dysfunction with impaired respiratory, cardiovascular, renal, haemostatic, haemopoietic, hepatic and cerebral function. Carbimazole was stopped and ceftazidime and netilmicin were started empirically. She was resuscitated with fluid and commenced on dobutamine (8 p,g/kg/min) . Her blood pressure responded to the fluid resuscitation, but her heart and respiratory rates remained elevated for the next 24 hours. It remained difficult to distinguish the hyperdynamic state from that of thyrotoxicosis. Dobutamine was stopped and later an esmolol infusion was started (50 p,g/kg/min) with a subsequent decrease in heart rate to llO/min. Esmolol was continued for two days because of the risk of a thyrotoxic crisis. Fresh frozen plasma and platelet concentrates were given to arrest her worsening coagulopathy.
Her white cell count remained low at 0.6 x 10 9 11. A bone marrow aspirate revealed hypocellular marrow with myeloid lineage showing maturation arrest, an increased ratio of plasma cells with adequate iron stores and megakaryocytes. In view of this evidence of agranulocytosis and her critically ill condition a trial of GM-CSF 600 p,g daily subcutaneously was instituted. By day 3 of GM-CSF therapy her white cell count had risen to 2.8 x 10-9 with a return of granulocytes to the peripheral blood film. Both the granulocyte and total white cell counts continued to rise. Changes in granulocytes and other white cells are shown in Figure 1 . 
Days of GM-CSF Therapy Over the next 24 hours she made a rapid recovery, with improvement in oxygenation, haemodynamic stability, and complete resolution of her renal impairment. Five days after admission her white cell count had risen to 12.5 X 10 9 11 and she was transferred to the general ward. The final dose of GM-CSF was given the following day when her white cell count was 14.8 x 10 9 /1. Her white cell count stabilised at 8-Il x 10 9 /1 and she proceeded to make a complete recovery to discharge one week later.
A primary source of the bacteraemia was never confirmed although pneumonia was suspected. Her admission thyroid function tests revealed a mildly elevated free T4 level at 25.2 pmolll (normal range 10.2-19.6 pmolll), with a TSH level of 0.28 mIU/l 
DISCUSSION
Agranulocytosis is a rare but potentially lethal complication of drug therapy. It Anti-thyroid drug-induced agranulocytosis usually resolves over a period of two to three weeks with peripheral granulocytes not rising above 1.5 x 10 9 /1 for at least 5 days'O, In the case described there was a more rapid recovery from agranulocytosis. The short latency between initiation of GM-CSF therapy and the rise of the white cell count corresponds to the time taken for stimulation, maturation and release of granulocytes".
Although a number of features would be consistent with thyrotoxic crisis, including mildly deranged thyroid function tests, this diagnosis cannot explain her hypotension in the presence of normal left ventricular size and function. In addition, she recovered without specific anti-thyroid therapy. A more likely explanation is the presence of severe sepsis secondary to Klebsiella pneumonia in a neutropenic patient.
Neutropenia associated with bacteraemia, septic shock and respiratory failure has an exceedingly poor prognosis". In the case described above the raw APACHE 11 score for the first 24 hours was 27, with a predicted mortality of 79070".
The use of GM-CSF has been described for druginduced neutropenia'·6,'4. The role of exogenous colony stimulating factors in the routine treatment of agranulocytosis without infection has been questioned's. The therapeutic use of GM-CSF has been associated with thyroid dysfunction, haemolysis, "leaky capillary syndrome", fever, and reactivation of rheumatoid arthritisl4. A number of endogenouslyproduced stimulating factors such as G-CSF, macrophage colony stimulating factor and interleukin-6 are elevated in sepsis and during the recovery phase of drug-induced agranulocytosis'6. Unlike other factors, serum levels of GM-CSF are not usually elevated in sepsis, although gram negative bacteraemia does cause mild elevation'6. GM-CSF may play a more localized role in maturation of marrow cell series.
Colony stimulating factors have been used experimentally in non-neutropenic animal models and patients. Improved survival by improved gut barrier function and modulation of bacterial clearance with GM-CSF use has been shown in two rodent models'7. GM-CSF has been shown to reduce the mortality and morbidity during severe fungal infections in patients'S.
The more specific G-CSF was unavailable to us. The stimulation of granulocyte production by G-CSF is sixfold greater than equivalent doses of GM-CSF and has a lower potential for drug associated morbidity. Hence G-CSF may be clinically superior to GM-CSF.
Agranulocytosis increases the risk of infection and severe infection in the presence of agranulocytosis carries a very poor prognosis' 2 .' 4
• Thus the recovery of a normal white cell count following CSF therapy should be associated with improved outcome. Clinical studies to substantiate this are not yet available.
Thus the presence of severe sepsis with neutropenia, as in our case, justifies the use of growth stimulating factors. Our patient experienced a remarkably benign course for her illness and proceeded to make a full and rapid recovery despite potentially life-threatenirtg neutropenia, bacteraemia and early multi-organ dysfunction.
In view of the often reversible nature of drug-induced agranulocytosis, patients presenting with this condition complicated by sepsis should be considered for early colony stimulating factor therapy.
